Skip to main content
COVID-19

Horizon Preferred Medical Drug List

Horizon formularies encourage the use of safe, effective and affordable drugs by our members.

Through our Preferred Medical Drug List initiative, our Pharmacy and Therapeutic (P&T) Committee identifies preferred medical drug products in a variety of categories and implements strategies to encourage the use of effective and lower cost medicines. Horizon also collaborates with health system partners to align strategies to ensure a seamless transition of care.

The P&T committee is composed of independent practicing physicians, epidemiologists, pharmacists and key thought leaders/specialists for their clinical expertise.

The P&T Committee reviews new drugs in the pipeline as well as existing products. They look at drug utilization patterns, medical literature evaluation, efficacy parameters, safety concerns, drug policies, site of care and comparative effectiveness. They also evaluate post-marketing surveillance data review, case reviews and outcomes associated with total cost of care as well as the trends across benefit design.

Currently, Horizon’s Preferred Medical Drug List includes 94 drug products within the following categories.

  • Antiemtics
  • Bone Resorption Inhibitors (osteoporsosi)
  • Bendamustines
  • Botulinum Toxins
  • Colony-Stimulating Factors (Short Acting)
  • Colony-Stimulating Factors (Long Acting)
  • Contraceptives
  • Enzyme Replacement Therapy (Gaucher’s)
  • Erythropoiesis-Stimulating Agents
  • Folinic Acid
  • Intravenous Immune Globulin
  • Iron, Intravenous
  • Oncology/Bevacizumab
  • Oncology/Rituximab
  • Oncology/Taxanes
  • Oncology/Trastuzumab
  • Ophthalmic Injections
  • Viscosupplemtation

Details about specific preferred drugs can be reviewed within the guidelines of policies within our Medical Policy Manual.

  • Type a drug name or keyword into the search field to locate appropriate policy content.
Published on: September 13, 2021, 22:33 p.m. ET
Last updated on: September 8, 2021, 13:31 p.m. ET